Lilly signs GLP-1 deal with Hims as Alnylam sales chief exits

· Health · United States

Eli Lilly and Hims reached a GLP-1 deal, marking a course change for Hims, which had previously sold knockoff versions of the weight-loss drugs. The arrangement was reported by BioPharma Dive alongside other industry moves, including Alnylam's chief commercial officer stepping down and a medicine recently acquired by Servier failing a key trial. The deal signals that telehealth platforms are shifting from unauthorized compounded alternatives toward branded supply agreements with the manufacturers of the blockbuster obesity drugs.

Why it matters：The deal shows how telehealth channels are being folded into branded GLP-1 distribution, a shift that could reshape pricing and access for obesity drugs.

Key points

  • Hims had previously sold compounded versions of GLP-1 drugs.
  • Alnylam's chief commercial officer is leaving the company.
  • A Servier-acquired medicine failed a key trial.

Sources (original reporting)

More stories from this day